SQLite Web: event

seq

Primary key. INTEGER

id

TEXT NOT NULL

kind

TEXT NOT NULL

ts

TEXT NOT NULL

actor

TEXT

subject_entity_ids

TEXT

payload

{"created_at":"2026-04-22T06:06:10.858527+00:00","dedupe_key":"signal_enriched:discovery_unusual_volume_delta:cc27a687dbf7d799","evidence_event_ids":["evt_874ff1689279"],"signal_type":"discovery_unusual_volume_delta","source":"discovery_ingestor","value":{"aggregator_url":"https://www.nasdaq.com/articles/maze-therapeutics-prices-150-mln-stock-pre-funded-warrants-offering","as_of":"2026-04-22T06:06:10.858527+00:00","canonical_url":"https://www.rttnews.com/3640971/maze-therapeutics-prices-150-mln-stock-pre-funded-warrants-offering.aspx","enrichment":{"aggregator_url":"https://www.nasdaq.com/articles/maze-therapeutics-prices-150-mln-stock-pre-funded-warrants-offering","article_chars":1205,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_357c95eedf0fa21a","canonical_host":"rttnews.com","canonical_is_aggregator":false,"canonical_url":"https://www.rttnews.com/3640971/maze-therapeutics-prices-150-mln-stock-pre-funded-warrants-offering.aspx","content_type":"text/html; charset=utf-8","enriched_at":"2026-04-22T06:07:42.356156+00:00","extraction_method":"trafilatura","fetched_description":"(RTTNews) - Maze Therapeutics, Inc. (MAZE), a clinical-stage biopharmaceutical company, on Wednesday, announced the pricing of an underwritten registered offering of stock and pre-funded warrants expected to raise approximately $150 million in gross proceeds.","fetched_title":"Maze Therapeutics Prices $150 Mln Stock, Pre-Funded Warrants Offering | Nasdaq","final_url":"https://www.nasdaq.com/articles/maze-therapeutics-prices-150-mln-stock-pre-funded-warrants-offering","html_truncated":false,"paywall_likely":false,"publisher_domain":"rttnews.com","publisher_resolution":"canonical_url","requested_url":"https://www.nasdaq.com/articles/maze-therapeutics-prices-150-mln-stock-pre-funded-warrants-offering","source_event_id":"evt_874ff1689279","source_quality":"medium","status_code":200,"version":"signal_enrichment_v2"},"fp":"3c1488db0c76b06b","kind":"unusual_volume","published_at":"2026-04-22T05:16:23+00:00","publisher_domain":"rttnews.com","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["Wednesday","Tuesday","April 23","into 2029"],"entities":[{"asset_class":"equity","name":"Maze Therapeutics, Inc.","relevance":"high","symbol":"MAZE","type":"company"},{"asset_class":"other","name":"Nasdaq","relevance":"medium","symbol":"","type":"exchange"}],"event_type":"listing","information_gaps":["Unusual volume delta details are not provided: baseline volume, volume ratio vs average, and direction are missing.","The signal does not state whether the volume move (if any) is confirmed by news coverage beyond the offering announcement, nor does it explicitly link volume to a catalyst beyond the described financing event.","No explicit catalyst hypothesis for unusual volume is stated in the provided text; only the offering and related use of proceeds are described."],"key_facts":["Maze Therapeutics announced the pricing of an underwritten registered offering of stock and pre-funded warrants expected to raise approximately $150 million in gross proceeds.","The offering includes 5.54 million shares of common stock priced at $23.50 per share.","The company is offering pre-funded warrants to purchase up to 850,000 shares at a price of $23.499 per warrant.","The offering is expected to close on or about April 23.","Proceeds are expected to be used primarily to advance research and development of product candidates, including MZE829 (APOL1-mediated kidney disease) and MZE782 (phenylketonuria and chronic kidney disease), and for general corporate purposes.","The company expects net proceeds (combined with existing cash and marketable securities) to fund operations into 2029.","On Tuesday, Maze Therapeutics closed trading 4.28% lower at $25.69 on the Nasdaq; after-hours trading was 1.01% higher at $25.95 on the Nasdaq."],"numeric_claims":[{"label":"gross_proceeds_target_usd_mln","value":"~150 million"},{"label":"common_shares_offered_mln","value":"5.54 million"},{"label":"common_share_price_usd","value":"23.50"},{"label":"pre_funded_warrants_shares_max","value":"850,000"},{"label":"pre_funded_warrant_price_usd","value":"23.499"},{"label":"offering_close_timing","value":"on or about April 23"},{"label":"tuesday_close_change_pct","value":"-4.28%"},{"label":"tuesday_close_price_usd","value":"25.69"},{"label":"after_hours_change_pct","value":"+1.01%"},{"label":"after_hours_price_usd","value":"25.95"}],"primary_claim":"Maze Therapeutics priced an offering of 5.54 million shares of common stock at $23.50 per share plus pre-funded warrants for up to 850,000 shares, targeting approximately $150 million in gross proceeds.","relevance_score":0.62,"sentiment":"mixed","source_quality":"medium","summary":"Maze Therapeutics (MAZE) priced an underwritten registered offering of common stock and pre-funded warrants expected to raise about $150 million in gross proceeds. The company said proceeds will primarily fund R&D for its product candidates and general corporate purposes, with operations funded into 2029.","topics":["equity offering","pre-funded warrants","capital raise","biopharmaceutical financing","MAZE","R&D funding"]},"source":"Nasdaq Markets","source_domain":"rttnews.com","summary":"(RTTNews) - Maze Therapeutics, Inc. (MAZE), a clinical-stage biopharmaceutical company, on Wednesday, announced the pricing of an underwritten registered offering of stock and pre-funded warrants expected to raise approximately $150 million in gross proceeds.","tickers":["MAZE"],"title":"Maze Therapeutics Prices $150 Mln Stock, Pre-Funded Warrants Offering","url":"https://www.rttnews.com/3640971/maze-therapeutics-prices-150-mln-stock-pre-funded-warrants-offering.aspx"}}

TEXT NOT NULL

source_ref

TEXT

confidence

REAL (default 0.0

dedupe_key

TEXT

episode_id

TEXT

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

event_store.db — events

Update row 479398 in events